Process outcome, Practitioner Impact 1. Polypharmacy at · patients with schizophrenia or related psychoses
It is very uncertain whether active education + Support for implementation changes process outcome, Practitioner Impact 1. Polypharmacy at compared with routine care or Passive dissemination (very low certainty).
1 finding from 1 review
Process outcome, Practitioner Impact: 2. Not screened for cardiovascular risk, Framingham score (corrected for design effect) · patients with schizophrenia or related psychoses
It is very uncertain whether active education + Support for implementation changes process outcome, Practitioner Impact: 2. Not screened for… compared with routine care or Passive dissemination (very low certainty).
1 finding from 1 review
Patient outcome: Global state: average score (PANSS total, high = poor) · patients with schizophrenia or related psychoses
1 finding from 1 review
Patient outcome: satisfaction with care: average score (ZUF8, high = better satisfaction) · patients with schizophrenia or related psychoses
1 finding from 1 review
Patient outcome: treatment adherence: not adherent at · patients with schizophrenia or related psychoses
It is very uncertain whether active education + Support for implementation changes patient outcome: treatment adherence: not adherent at compared with routine care or Passive dissemination (very low certainty).
1 finding from 1 review
Drug attitude—DAI · patients with schizophrenia or related psychoses
1 finding from 1 review
Patient outcome: Quality of life · patients with schizophrenia or related psychoses
1 finding from 1 review
Mental state · patients with schizophrenia
1 finding from 1 review
Mental state: 3. Negative symptoms ‐ average endpoint score PANSS negative subscore · patients with schizophrenia
1 finding from 1 review
Quality of life: clinically important change in quality of life · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse effects/events: at least 1 adverse effect ‐ as defined by individual studies. · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Leaving the study early · patients with schizophrenia
1 finding from 1 review
Cognitive functioning Clinically important change in cognitive functioning as defined by each study · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Functioning: specific ‐ social ‐ clinically important change · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Prodromal symptoms: transition to psychosis Endpoint data (events) · people in the prodromal stage of psychosis
1 finding from 1 review
Global state: clinically important change in global state · people in the prodromal stage of psychosis
1 finding from 1 review
Mental state: psychosis risk symptoms SOPS total (higher score = worse, scale from: 0‐114) · people in the prodromal stage of psychosis
1 finding from 1 review
Behaviour: clinically important change in behaviour · people in the prodromal stage of psychosis
1 finding from 1 review
Adverse effects: at least one serious adverse event · people in the prodromal stage of psychosis
1 finding from 1 review
Quality of life: clinically important change in quality of life · people in the prodromal stage of psychosis
1 finding from 1 review